Oculus Innovative Sciences, Inc. announced it has finalized a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations based upon the company's Lipogrid® Technology.
Industry News
-
-
The U.S. Food and Drug Administration approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition. Defitelio is marketed by Jazz Pharmaceuticals based in Palo Alto, California.
-
The U.S. Food and Drug Administration today announced the availability of an investigational test to screen blood donations for Zika virus. The screening test may be used under an investigational new drug application (IND) for screening donated blood in areas with active mosquito-borne transmission of Zika virus. The test is manufactured by Roche Molecular Systems, Inc., based in Branchburg, New Jersey.
[adsense:336x280:8701650588]
-
Natco Pharma decided to sales its US based pharmacy store. Natco decided in thier board meeting to sale of its Save Mart Store in the USA.
-
Natco Pharma Limited notified that an inspection was conducted by the United States Food & Drug Administration (USFDA) in two of its manufacturing facilities.
-
Adaptimmune Therapeutics plc announced that the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development has granted orphan drug designation for the company’s affinity enhanced T-cell therapy targeting NY-ESO for the treatment of soft tissue sarcoma, a solid tumor cancer.
-
Sun Pharma acquired established prescription brands from Novartis AG and Novartis Pharma AG (together Novartis) in Japan. In a USD 293 million cash deal Indias Sun Pharmaceutical Industries Ltd. has agreed to buy 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, the Indian company said.
In a statement issued late Tuesday the company said that a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of USD 293 million.
"These brands have combined annualised revenues of approximately USD 160 million and address medical conditions across several therapeutic areas," the company said.
"Under the terms of the agreements, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorisations to Sun Pharma's subsidiary."
The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The partner will also be responsible for distribution of the brands.
Commenting on the acquisition, Dilip Shanghvi, Managing Director, Sun Pharma said, “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.”
As per the December-2015 IMS Data, the size of the Japanese pharmaceutical market was estimated at USD 73 billion, accounting for over seven percent of the USD 1 trillion global pharmaceutical market.
-
Chugai Pharmaceutical Co., Ltd. and Maruho Co., Ltd. announced that Chugai has acquired the marketing approval of "Marduox® Ointment" (Marduox) for the indication of psoriasis vulgaris, which has been jointly developed by Chugai and Maruho.
-
Eagle Pharmaceuticals, Inc. announced that it has entered into an agreement with the National Institutes of Health (“NIH”)/National Institute on Drug Abuse (“NIDA”) to explore the use of Ryanodex® in the treatment of hyperthermia related to MDMA (“Ecstasy”) and Methamphetamine intoxication, which is a life-threatening condition mostly affecting adolescents and young adults.
-
- Read more about TSO3 receives FDA 510(k) clearance for universal design of STERIZONE® VP4 Sterilizer
TSO3 Inc. has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a universal design of its STERIZONE® VP4 Sterilizer. The STERIZONE® VP4 Sterilizer was originally cleared for commercialization in the U.S. in December 2014. The new clearance enables the company to streamline assembly and shipping around a single sterilizer platform that meets global regulations for electromechanical design.
RECOMMENDED POSTS
Subscribe with us
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
